These findings unveil a novel regulatory axis involving IGFBP2 and CXCL1 in the development of gefitinib resistance, providing valuable insights for the development of prognostic models and intervention strategies in precision therapy for lung cancer patients resistant to gefitinib. This evidence concerns the gene IGFBP2 and lung carcinoma.